Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial - Oza, Amit M.; Matulonis, Ursula A.; Malander, Susanne; Hudgens, Stacie; Sehouli, Jalid; del Campo, Josep M.; Berton-Rigaud, Dominique; Banerjee, Susana; Scambia, Giovanni; Berek, Jonathan S.; Lund, Bente; Tinker, Anna V.; et al. (LANCET ONCOLOGY, 2018)